BRPI0911451A2 - biomarcadores para eficácia medicamentosa de egfr/her/erb - Google Patents

biomarcadores para eficácia medicamentosa de egfr/her/erb

Info

Publication number
BRPI0911451A2
BRPI0911451A2 BRPI0911451A BRPI0911451A BRPI0911451A2 BR PI0911451 A2 BRPI0911451 A2 BR PI0911451A2 BR PI0911451 A BRPI0911451 A BR PI0911451A BR PI0911451 A BRPI0911451 A BR PI0911451A BR PI0911451 A2 BRPI0911451 A2 BR PI0911451A2
Authority
BR
Brazil
Prior art keywords
erb
biomarkers
egfr
drug efficacy
efficacy
Prior art date
Application number
BRPI0911451A
Other languages
English (en)
Inventor
W Grunt Thomas
Shabbir Waheed
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of BRPI0911451A2 publication Critical patent/BRPI0911451A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0911451A 2008-05-25 2009-05-21 biomarcadores para eficácia medicamentosa de egfr/her/erb BRPI0911451A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5601608P 2008-05-25 2008-05-25
PCT/US2009/044771 WO2009151908A1 (en) 2008-05-25 2009-05-21 Biomarkers for egfr/her/erbb drug efficacy

Publications (1)

Publication Number Publication Date
BRPI0911451A2 true BRPI0911451A2 (pt) 2019-09-24

Family

ID=41078344

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0911451A BRPI0911451A2 (pt) 2008-05-25 2009-05-21 biomarcadores para eficácia medicamentosa de egfr/her/erb

Country Status (4)

Country Link
AU (1) AU2009257802A1 (pt)
BR (1) BRPI0911451A2 (pt)
CA (1) CA2722890A1 (pt)
WO (1) WO2009151908A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2787048C (en) * 2010-01-13 2021-06-22 Wyeth Llc A cut-point in pten protein expression that accurately identifies tumors and is predictive of drug response to a pan-erbb inhibitor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR056857A1 (es) * 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
WO2007106503A2 (en) * 2006-03-13 2007-09-20 Osi Pharmaceuticals, Inc. Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
JP2010500577A (ja) * 2006-08-07 2010-01-07 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 癌の予後および予測シグナチャーのプロテオミクスパターン

Also Published As

Publication number Publication date
AU2009257802A1 (en) 2009-12-17
CA2722890A1 (en) 2009-12-17
WO2009151908A1 (en) 2009-12-17

Similar Documents

Publication Publication Date Title
BRPI0920521A2 (pt) combinação farmacêutica
BRPI0919548A2 (pt) pacote para inserto
BRPI0912271A2 (pt) co-autoria estruturada
DK2310071T3 (da) Ekkogen medicinsk kanyle
DK2342454T3 (da) Vindkraftanlæg
DK2837348T3 (da) Kryokirurgiske fremgangsmåder
EP2307774A4 (en) PRESSURE RELIEF VALVE
EP2135921A4 (en) M-C-N-O-fluorescer
EP2377874A4 (en) Antioxidant
DK2300238T3 (da) Skyggebillede-sikkerhedstræk
BRPI0922884A2 (pt) compostos para tratamento de câncer
DK2310613T3 (da) Forbedret brudled til stigrør
BRPI0909287A2 (pt) Retenção
EP2280264A4 (en) STANDARD AGENTS
DK2271618T3 (da) Farmaceutiske forbindelser
BRPI0907863A2 (pt) pirrolopirimidinacarboxamidas
FI20085425A0 (fi) Sulfaattiesihydrolyysikeittomenetelmä
BRPI0917718A2 (pt) calçado
BRPI0916990A2 (pt) Combinações inseticidas
BRPI0913872A2 (pt) multi-bandagem
BRPI0918508A2 (pt) orto-aminoanilidas para o tratamento de câncer
BRPI0919750A2 (pt) transmissão
EP2320211A4 (en) SPECTROMETER
ITBS20080008A1 (it) Lampada
ITBS20080009A1 (it) Lampada

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law
B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.